idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
04/11/2025 20:00

New pathoblocker is to stop Salmonella infections early on

Christfried Dornis Hochschulkommunikation
Eberhard Karls Universität Tübingen

    Team from the University of Tübingen and the German Center for Infection Research discovers a substance that inhibits signaling pathways of pathogens as they invade a cell

    Pathogenic Salmonella injects effector proteins into the cells of the gastrointestinal tract to penetrate and multiply within them. The bacteria are usually ingested with contaminated food. They can cause serious gastrointestinal inflammation and even systemic infections. Now, an international research team led by Professor Samuel Wagner of the University of Tübingen Cluster of Excellence “Controlling Microbes to Fight Infections“ (CMFI) and the German Center for Infection Research (DZIF) have discovered a substance that can stop the process of infection early on. The synthetic substance C26 inhibits the injection of effector proteins. It could be developed into a drug for combating Salmonella infections in humans and animals. The discovery has been published in the journal Science Advances.

    Salmonella has developed multiple resistance mechanisms to antibiotics which inhibit its growth or kill the bacteria. As a result, a treatment alternative is needed urgently. Pathoblockers present such an alternative. The discovered substance acts early, before the bacteria penetrate the tissues, by specifically targeting and disrupting the infectious mechanisms of the pathogen. “As a medication, they have a very specific and targeted effect against Salmonella. According to today’s knowledge, the probability would therefore be much lower that the Salmonella would acquire resistance against these substances from other bacteria,” says Samuel Wagner.

    Targeting the central regulator

    While attacking their target tissue in the gastrointestinal tract, Salmonella set in motion secretion systems, that rely on several (transcriptional) regulators. “Among these regulators, one named HilD, has a central role in the entry of Salmonella into the host cell. We were able to find a suitable target within the structure of HilD to identify new drug candidates,” says Dr. Abdelhakim Boudrioua of the CMFI Cluster of Excellence and first author of the study. In order to transmit signals for protein synthesis, the regulators must bind highly specifically to other regulators and DNA and trigger further reactions. It turns out that HilD has a druggable pocket. On a molecular level, it can be imagined as an intricately shaped, three-dimensional pocket. The researcher explains that the discovered substances fit precisely in this pocket and as a result, disrupt the function of the regulator. In this way, the process of infection can be stopped, he continues.

    The research team screened large compound libraries for potential candidates. “We were able to identify C26 as a promising substance. We then proceeded with an extensive analysis of its mode of action and its precise binding site on the structure of HilD,” says Boudrioua. Numerous tests of the efficiency of C26 in disrupting infection followed, for example by proving that the inhibitor interferes with the pathogenicity of bacteria hiding inside macrophages – the cells of the immune system of the host. “According to our results, C26 could stop the process of Salmonella infection early on at the central regulator HilD. It seems to have a specific effect on the pathogen and does not disturb the beneficial human microbiome.” He adds, “We now have a suitable precursor for further drug development.”

    “The discovery impressively underlines how our excellent basic research at the University of Tübingen produces innovative solutions for urgent medical problems,” adds Professor Dr. Dr. h.c. (Dōshisha) Karla Pollmann, President and Vice-Chancellor of the University of Tübingen.

    A long way to a pharmaceutical

    Yet Wagner says the route to treating Salmonella infections with pathoblockers such as HilD inhibi-tors is long. Aside from human use, these treatments could also be developed for veterinary medicine, particularly for poultry. The efforts could be worth it. Unlike antibiotics, which also damage the patients’ useful intestinal bacteria in many ways, Wagner says specific pathoblockers are not expected to have any negative effects on the body and its own microbiome.


    Contact for scientific information:

    Prof. Dr. Samuel Wagner
    University of Tübingen
    Interfaculty Institute of Microbiology and Infection Medicine (IMIT)
    Cluster of Excellence “Controlling Microbes to Fight Infections” (CMFI)
    German Center for Infection Research
    Phone +49 7071 29-84238
    samuel.wagner[at]med.uni-tuebingen.de

    Dr. Abdelhakim Boudrioua
    University of Tübingen
    Interfaculty Institute of Microbiology and Infection Medicine (IMIT)
    Cluster of Excellence “Controlling Microbes to Fight Infections” (CMFI)
    German Center for Infection Research
    Phone +49 7071 29-81514
    abdelhakim.boudrioua[at]med.uni-tuebingen.de


    Original publication:

    Abdelhakim Boudrioua, Joe D. Joiner, Iwan Grin, Thales Kronenberger, Vadim S. Korotkov, Wieland Steinchen, Alexander Kohler, Sophie Schminke, Julia-Christina Schulte, Michael Pietsch, Arun Naini, Simon Kalverkamp, Sven-Kevin Hotop, Travis Coyle, Claudio Piselli, Murray Coles, Katharina Rox, Matthias Marschal, Gert Bange, Antje Flieger, Antti Poso, Mark Brönstrup, Marcus D. Hart-mann, Samuel Wagner: Discovery of synthetic small molecules targeting the central regulator of Salmonella pathogenicity. Science Advances, https://doi.org/10.1126/sciadv.adr5235


    Images

    Cut through a protein: Look inside the HilD Regulator and the binding site for the pathoblocker. The discovered substance C26 (blue) bound to the HilD regulator and acting as pathoblocker.
    Cut through a protein: Look inside the HilD Regulator and the binding site for the pathoblocker. The ...
    Leon Kokkoliadis
    Leon Kokkoliadis/CMFI, University of Tübingen

    A detailed view of the interior of a protein. The identified pathoblocker C26 (blue) has been shown to bind to the HilD-Regulator. The figure also illustrates the protein structure as predicted by AlphaFold (black)
    A detailed view of the interior of a protein. The identified pathoblocker C26 (blue) has been shown ...
    Leon Kokkoliadis
    Leon Kokkoliadis/CMFI, University of Tübingen


    Criteria of this press release:
    Journalists
    Biology, Medicine
    transregional, national
    Research results
    English


     

    Cut through a protein: Look inside the HilD Regulator and the binding site for the pathoblocker. The discovered substance C26 (blue) bound to the HilD regulator and acting as pathoblocker.


    For download

    x

    A detailed view of the interior of a protein. The identified pathoblocker C26 (blue) has been shown to bind to the HilD-Regulator. The figure also illustrates the protein structure as predicted by AlphaFold (black)


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).